MedPath
HSA Approval

NIFETEX-TR CAPSULE

SIN07439P

NIFETEX-TR CAPSULE

NIFETEX-TR CAPSULE

May 24, 1993

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Therapeutic

Prescription Only

Formulation Information

CAPSULE

**DOSAGE AND ADMINISTRATION** Adults: Hypertension one capsule daily. Adults: Angina one capsule daily. If necessary, additional Nifedipine or prophylactic nitrate therapy.

ORAL

Medical Information

**INDICATIONS** All grades of Hypertension and Angina.

**CONTRAINDICATIONS** NIFETEX-TR should be used with caution in patients with impaired renal function. Since Nifedipine may cause a decrease in peripheral resistance, careful monitoring of blood pressure during initial stages of therapy is suggested. Care has to be taken in patients with conduction defects or poor cardiac reserve. Care should be taken when co-administered with class one antidysrhythmic agents and with anaesthetics, caution in patients with chronic obstructive airways disease and asthma. Caution should be taken in transferring patients from clonidine. Diabetes patients may require adjustment of their drug therapy.

C08CA55

nifedipine, combinations

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

WINTAC LIMITED

STERIL-GENE LIFE SCIENCES (P) LIMITED

Active Ingredients

NIFEDIPINE

20 mg

Nifedipine

ATENOLOL

50 mg

Atenolol

Documents

Package Inserts

Nifetex-TR capsules PI.pdf

Approved: August 24, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath